AIDA - CAS 168560-79-0
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
Molecular Weight:
AIDA is a selective group I mGluR agonist and could show centrally active following systemic administration in vivo.
≥98% by HPLC
White Solid
(RS)-1-Aminoindan-1,5-dicarboxylic acid
Canonical SMILES:
1.The anxiolytic-like activity of AIDA (1-aminoindan-1,5-dicarboxylic acid), an mGLu 1 receptor antagonist.
Kłodzińska A;Tatarczyńska E;Stachowicz K;Chojnacka-Wójcik E J Physiol Pharmacol. 2004 Mar;55(1 Pt 1):113-26.
In the present study we examined the effects of 1-aminoindan-1,5-dicarboxylic acid (AIDA), regarded as a selective and competitive mGluR1 antagonist, in animal models of anxiety. Diazepam (1-10 mg/kg) was used as a reference drug. After intraperitoneal administration, AIDA (0.5-2 mg/kg) produced anxiolytic-like effects in the conflict drinking test and the elevated plus-maze test in rats; however, in doses up to 8 mg/kg, it was inactive in the four-plate test in mice. AIDA tested at the effective doses in the conflict drinking test changed neither the treshold current nor water intake in rats compared to vehicle treatment. AIDA (in a dose of 4 mg/kg, but not lower) increased the exploratory locomotor activity of rats measured in the open-field test, but it did not disturb rat motor coordination in the rota-rod test. The above results indicate that selective mGluR1 antagonist AIDA induces antianxiety-like effects at a low risk of acute side effects characteristic of benzodiazepines. Further studies are required to identify the sites and the mechanism of action of AIDA.
2.Activation of mGlu1 but not mGlu5 metabotropic glutamate receptors contributes to postischemic neuronal injury in vitro and in vivo.
Meli E;Picca R;Attucci S;Cozzi A;Peruginelli F;Moroni F;Pellegrini-Giampietro DE Pharmacol Biochem Behav. 2002 Sep;73(2):439-46.
In order to investigate the involvement of mGlu1 and mGlu5 metabotropic glutamate receptors in the development of postischemic neuronal death, we examined the effects of selective agonists and antagonists in models of cerebral ischemia in vitro and in vivo. In murine cortical cell cultures and rat organotypic hippocampal slices exposed to oxygen and glucose deprivation (OGD), the mGlu1 antagonists 1-aminoindan-1,5-dicarboxylic acid (AIDA; 300 microM), (S)-(+)-2-(3'-carboxybicyclo[1.1.1]pentyl)-glycine (CBPG; 300 microM), 7-hydroxyiminocyclopropan[b]chromen-1a-carboxylic acid ethyl ester (CPCCOEt; 10-30 microM) and (+)-2-methyl-4-carboxyphenylglycine (LY367385; 30-100 microM) reduced neuronal loss when added to the medium during OGD and the subsequent 24-h recovery period. On the contrary, the potent and selective mGlu5 antagonist methyl-6-(phenylethynyl)-pyridine (MPEP; 0.1-1 microM) did not exhibit neuroprotection in any of these in vitro models. Incubation with the nonselective mGlu1 and mGlu5 agonist 3,5-dihydroxyphenylglycine (3,5-DHPG; 300 microM) but not with the mGlu5 agonist (RS)-2-chloro-5-hydroxyphenylglycine (CHPG; 1 mM) enhanced the severity of OGD-induced neuronal damage.
3.Morphine induction of c-fos expression in the rat forebrain through glutamatergic mechanisms: role of non-n-methyl-D-aspartate receptors.
Garcia MM;Anderson AT;Edwards R;Harlan RE Neuroscience. 2003;119(3):787-94.
Acute injection of morphine induces expression of the immediate-early genes c-Fos and JunB in several forebrain regions of the rat, in part through an N-methyl-D-aspartate (NMDA) receptor-dependent mechanism. Because membrane depolarization through (RS)-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) glutamate receptors is believed to be necessary for full activation of NMDA receptors, we determined the role of AMPA receptors in morphine-induced c-Fos expression. Rats were given the AMPA receptor antagonist GYKI-52466 (12.9 mg/kg, i.p.) 15 min before morphine (10 mg/kg, s.c.), or the AMPA receptor enhancer CX516 (30 mg/kg, i.p.) 5 min after morphine. The c-Fos response was attenuated by the antagonist and augmented by the enhancer. Using double immunocytochemistry, we found that morphine induced c-Fos in neurons containing the GluR2/3, but not the GluR1 and rarely the GluR4, subunits of the AMPA receptor. Double immunocytochemistry for mu opioid receptor and c-Fos showed that c-Fos expression was mainly absent in the patch compartment of the striatum, which is enriched in mu opioid receptors. The glutamatergic synapse often contains metabotropic receptors as well as ionotropic receptors.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related mGluR Products

CAS 781652-57-1 CDPPB

(CAS: 781652-57-1)

CDPPB is a positive allosteric modulator of mGlu5 receptor (EC50 = 10 and 20 nM for human and rat receptors, respectively). Study shows that CDPPB has a therape...

CAS 6971-97-7 DCB

(CAS: 6971-97-7)

DCB is an allosteric ligand for the metabotropic glutamate receptor mGlu5 that displays neutral modulation. It inhibits the modulation of mGlu5 by other alloste...

CAS 111900-32-4 (1S,3R)-ACPD

(CAS: 111900-32-4)

(1S,3R)-ACPD, an isomer of (±)-trans-ACPD, has been found to be an agonist of mGluRs.

CAS 327056-26-8 AZD 9272

AZD 9272
(CAS: 327056-26-8)

AZD 9272 is a potent, long-acting and selective nervous system penetrant mGlu5 antagonist with IC50 values of 2.6 and 7.6 nM for rat and human receptors, respec...

CAS 169209-63-6 (2R,4R)-APDC

(CAS: 169209-63-6)

(2R,4R)-APDC is a selective and relatively potent group II mGluR agonist (EC50 = 0.4, 0.4, > 100, > 100, > 300 and > 300 μM for human mGlu2, mGlu3, mGlu1, mGlu5...

CAS 871362-31-1 CTEP

(CAS: 871362-31-1)

CTEP is a novel, long-acting, orally bioavailable allosteric antagonist of mGlu5 receptor (IC50=2.2 nM), showing >1000-fold selectivity over other mGlu receptor...

CAS 85148-82-9 (S)-4-Carboxy-3-hydroxyphenylglycine

(CAS: 85148-82-9)

(S)-4C3H-PG has been found to be a competitive GluR1 glutamate receptor antagonist as well as metabotropic GluR2/3 glutamate receptor agonist.

CAS 872363-17-2 Dipraglurant

(CAS: 872363-17-2)

Dipraglurant is a mGlu5 receptor negative allosteric modulator. It is currently in phase II for the treatment of dyskinesia in Parkinson's disease.

Chemical Structure

CAS 168560-79-0 AIDA

Quick Inquiry

Verification code

Featured Items